CLDN18.2-CAR-iNKT cells

N/A

Report date: 2024/11/21 12:00:54

Base Information

Drug NameCLDN18.2-CAR-iNKT cells
Drug Alias NameALA-105CLDN18.2-iNKT
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionClaudin 18 protein modulators
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesArovella Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesArovella Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A